2026Eyl
DHR Sep 2026 · Reduce
Danaher Corporation (NYSE: DHR) receives a Reduce rating. While Danaher maintains wide economic moats rooted in regulatory switching costs across Cytiva bioprocessing consumables and entrenched clinical diagnostics platforms, the market is pricing in an aggressive margin recovery that leaves no margin of safety against ongoing customer facility commissioning deferrals and endemic respiratory testing normalization.Latest published research · analyzed 2026-09-25 · current · sources stale